Table 3 Pathological outcomes according to blinded independent pathological review in the ITT population

From: Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial

Variables

Cam+nab-TP (n = 132)

Cam+TP (n = 130)

TP (n = 129)

pCR

 Rate, % (95%CI)a

28.0 (20.6, 36.5)

15.4 (9.7, 22.8)

4.7 (1.7, 9.8)

 Difference (vs TP group), % (95%CI)b

23.5 (15.1, 32.0)

10.9 (3.7, 18.1)

 

 OR (vs TP group) (95%CI)b

8.11 (3.28, 20.06)

3.81 (1.48, 9.80)

 

 P value (vs TP group)c

<0.0001

0.0034

 

MPR

 Rate, % (95%CI)a

59.1 (50.2, 67.6)

36.2 (27.9, 45.0)

20.9 (14.3, 29.0)

 Difference (vs TP group), % (95%CI)b

38.3 (27.4, 49.3)

15.4 (4.7, 26.2)

 

 OR (vs. TP group) (95%CI)b

5.51 (3.18, 9.56)

2.19 (1.25, 3.84)

 
  1. a95%CI were calculated based on the Clopper-Pearson method.
  2. b95%CI for the stratification factor-adjusted rate differences were derived using the Mantel-Haenszel method.
  3. cThe Cochran-Mantel-Haenszel test, stratified by clinical stage (I/II versus III/IVA), was used to compare between groups.
  4. MPR, major pathological response.
Back to article page